QGEN
QIAGEN NV
NYSE · Healthcare · Medical - Diagnostics & Research · NL
$46.55
+0.91%Oct 6, 2026, 20:05 UTC
QIAGEN announced new AI capabilities for research and drug discovery, including IPA Investigator and the QIAGEN Discovery Platform.
Source:Oct 2, 2026, 16:09 UTC
Qiagen is reportedly in advanced talks with a strategic buyer regarding a potential acquisition.
Source:Sep 28, 2026, 18:38 UTC
Qiagen N.V. introduced a curated knowledge-graph foundation designed to ground AI agents used in drug discovery for biopharma companies.
Source:Sep 28, 2026, 05:30 UTC
The U.S. Food and Drug Administration cleared QIAGEN's new QIAstat-Dx panel for detecting gram-negative bacteria and antibiotic resistance markers, completing the company's U.S. bloodstream infection portfolio.
Source:Sep 24, 2026, 20:05 UTC
QIAGEN N.V. launched QIAmini, a compact automated sample preparation system for academic and research laboratories processing small sample batches.
Source:Sep 17, 2026, 14:37 UTC
TPG and Bain Capital emerged as potential bidders for Qiagen, with KKR, EQT and Advent also reportedly interested in acquiring the Dutch molecular diagnostics company, according to Manager Magazin.
Source:Aug 27, 2026, 20:05 UTC
QIAGEN N.V. announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction, building on its QIAsymphony platform with over 3,300 cumulative placements worldwide.
Source:Aug 24, 2026, 13:56 UTC
Qiagen N.V. announced that Jonathan M. Pratt will become CEO on September 1, 2026, succeeding Thierry Bernard, who will step down but support the transition through the end of the year.
Aug 10, 2026, 20:05 UTC
QIAGEN announced that the U.S. FDA cleared its QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.
Source:Aug 6, 2026, 00:31 UTC
Qiagen reported its financial results for the quarter ended June 2026, with revenue and earnings compared to Wall Street estimates and year-ago values.
Aug 4, 2026, 06:45 UTC
QBY announced the acquisition of a 51% stake in GITG, an SAP healthcare specialist based in Hamburg, on the day before the publication date.
Source:Jul 14, 2026, 20:05 UTC
QIAGEN launched the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel for bloodstream infection testing in Europe.
Source:Jun 15, 2026, 05:30 UTC
QIAGEN N.V. launched new additions to its QIAcuity digital PCR ecosystem, expanding gene expression capabilities and assay content for life sciences and biopharma applications.
Source: